INSMED Inc (INSM) earnings date
Feb 18, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 67% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 38 days, typically, give or take 8 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Thu, Oct 29, 2026 | before open | 29 | 8-K |
| Q2 FY2026 | Thu, Aug 6, 2026 | before open | 37 | 8-K |
| Q1 FY2026 | Thu, May 7, 2026 | before open | 37 | 8-K |
| Q4 FY2025 | Thu, Feb 19, 2026 | before open | 50 | 8-K |
| Q3 FY2025 | Thu, Oct 30, 2025 | before open | 30 | 8-K |
| Q2 FY2025 | Thu, Aug 7, 2025 | before open | 38 | 8-K |
| Q1 FY2025 | Thu, May 8, 2025 | before open | 38 | 8-K |
| Q4 FY2024 | Thu, Feb 20, 2025 | before open | 51 | 8-K |
What they guided beta
| Q3 FY2026 | "—Company Raises 2026 BRINSUPRI Revenue Guidance to $1.35 Billion to $1.4 Billion—" exhibit |
| Q3 FY2026 | "—Company Raises 2026 ARIKAYCE Revenue Guidance to $460 Million to $470 Million—" exhibit |
| Q3 FY2026 | "the low end of our full-year 2026 revenue guidance for both products." exhibit |
| Q3 FY2026 | "interstitial lung disease (PH-ILD) and expects to complete enrollment in the first half of 2028." exhibit |
| Q3 FY2026 | "Insmed continues to anticipate initiating a Phase 3 study of TPIP in patients with idiopathic pulmonary fibrosis (IPF) in the first half of 2027." exhibit |
| Q2 FY2026 | "—Company Raises 2026 BRINSUPRI Revenue Guidance to $1.25 Billion to $1.40 Billion—" exhibit |
| Q2 FY2026 | "—Company Reiterates 2026 ARIKAYCE Revenue Guidance of $450 Million to $470 Million—" exhibit |
| Q2 FY2026 | "Insmed continues to anticipate a regulatory decision for brensocatib for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in Japan in the second half of 2026." exhibit |
| Q2 FY2026 | "Insmed continues to anticipate initiating a Phase 3 study of TPIP in patients with progressive pulmonary fibrosis (PPF) in the second half of 2026 and a Phase 3 study in patients with idiopathic" exhibit |
| Q2 FY2026 | "The Company raised its guidance for full-year 2026 BRINSUPRI revenues to a range of $1.25 billion to $1.40 billion from the previous guidance of at least $1 billion." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/INSM
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/INSM
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/INSM/"><img src="https://veritasdata.dev/embed/INSM.svg" alt="INSM earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/INSM/)
Script
<script async src="https://veritasdata.dev/embed/INSM.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/INSM"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.